SCHEMBL7148722

SCHEMBL7148722

COc1ccc(CNC(=O)c2ccc3c(c2)c(=O)n(CCC(=O)O)c(=O)n3C)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
KDM4E B2RXH2 3/20 0.51
ALDH1A1 P00352 3/20 0.51
RECQL P46063 1/20 0.51
MMP13 P45452 2/20 0.51
RXFP1 Q9HBX9 2/20 0.50
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
PPARG P37231 1/20 0.47
POLB P06746 1/20 0.47
TP53 P04637 3/20 0.47
MAPK1 P28482 2/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
EPHX2 P34913 1/20 0.46
NR1H4 Q96RI1 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CYP2C9 P11712 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7623073 0.94 MAPT (0.54) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL7021095 0.92 MAPT (0.51) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL7627970 0.91 MAPT (0.52) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL7099302 0.90 MAPT (0.53) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL7104549 0.90 ALDH1A1 (0.53) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL6234634 0.89 MMP13 (0.58) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL6724632 0.88 MMP13 (0.53) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL6259580 0.88 MMP13 (0.61) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL6246256 0.88 MAPT (0.58) MAPTMEN1KMT2AKDM4EMMP13
SCHEMBL7627677 0.87 MAPT (0.55) MAPTMEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1368324-A1 QUINAZOLINES AS MMP-13 INHIBITORS Warner-Lambert Company LLC (US) 2003-12-10 EP claimed
US-20020193377-A1 Quinazolines as MMP-13 inhibitors ANDRIANJARA CHARLES (FR) 2002-12-19 US claimed
WO-2002064572-A1 QUINAZOLINES AS MMP-13 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO claimed
US-20020193377-A1 Quinazolines as MMP-13 inhibitors ANDRIANJARA CHARLES (FR) 2002-12-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193377-A1 Quinazolines as MMP-13 inhibitors MMP13, MMP9, MMP3 MAPT 4823/4885MEN1 4715/4885KMT2A 3258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.